[Asia Economy Reporter Hyunseok Yoo] NeoFact affiliate Ybrain announced on the 27th that it will officially launch Mindsteem, an electronic medicine for depression for home use.
Mindsteem is the first electronic medicine for depression in Korea and has been validated for efficacy and safety through marketing approval by the Ministry of Food and Drug Safety in April. Along with this, it completed the world's first 100% home-based approved clinical trial.
According to a domestic multicenter clinical trial conducted in 2020 to improve depression, applying Mindsteem alone for 30 minutes daily over 6 weeks resulted in a remission rate of depressive symptoms of 62.8%, showing about 24% higher symptom improvement compared to the remission rate of existing antidepressants (about 50%). Six university hospitals, including Catholic Seoul St. Mary's Hospital, Bundang Seoul National University Hospital, and Korea University Ansan Hospital, participated in the clinical trial.
Mindsteem is effective in improving depressive symptoms in patients with mild to moderate major depressive disorder and can be used at hospitals and at home with a prescription from a psychiatrist or other specialist.
It is a treatment method that normalizes the function of the impaired frontal lobe, the cause of depression, through a conveniently wearable micro electrical stimulator. Mindsteem incorporates more than 20 patented technologies related to new neurostimulation technology, automation for home use, safety, convenience, and hardware and software for remote management.
Ybrain has opened a purchase-only site within its website to first receive hospital purchase inquiries and demo applications. When an inquiry is left on the purchase site, a Ybrain representative explains how to use the product and proceeds with the purchase.
Professor Jeongho Chae of the Department of Psychiatry at Seoul St. Mary's Hospital, who participated in the clinical trial of Mindsteem, said, "Electronic medicine for depression is a safe treatment method that even pregnant women can use with confidence," adding, "It can be additionally applied without concerns about interactions with existing antidepressants and can be an alternative treatment for patients who have aversion to antidepressants."
Lee Giwon, CEO of Ybrain, said, "We hope that Mindsteem will create an active treatment atmosphere where the rapidly increasing number of depression patients due to COVID-19 can continuously continue treatment at home instead of hospitals," and added, "We plan to apply for sales approval from the US FDA next month."
Meanwhile, Ybrain plans to participate in CES 2022 held in Las Vegas to officially introduce Mindsteem to the US market. In addition to Mindsteem, the company will exhibit its psychiatric diagnostic system Mindscan and various electronic medicine product lineups for stress, migraines, dementia, etc., implementing the concept of an 'electronic pharmacy' that provides a total solution from diagnosis to treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
